- Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) $7.90. Synergy Pharma gaining after it announced positive top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in 1,346 adult patients with chronic idiopathic constipation (CIC).
previous post
next post